Participating Faculty: Improving Treatment Success Rates for Type 2 Diabetes: Balancing Safety, Cost, and Outcome

The American Journal of Managed Care

This supplement to summarizes key national treatment goals, and guidelines and algorithms for the management of type 2 diabetes mellitus (T2DM), and describes the role of some newer classes of antihyperglycemic medications, including incretin-related agents. It also summarizes the current understanding of T2DM health economics research, discusses the role and benefits of comparative effectiveness research in managed care decision making for T2DM, and describes key concepts associated with a value-based approach to managed care coverage of T2DM.

Faculty

Lawrence Blonde, MD, FACP, FACE

Director

Ochsner Diabetes Clinical Research Unit

Department of Endocrinology, Diabetes, and Metabolism

Ochsner Medical Center

New Orleans, LA

Viktor V. Chirikov, MS

Graduate Student

Pharmaceutical Health Services Research

University of Maryland School of Pharmacy

Baltimore, MD

Fadia T. Shaya, PhD, MPH

Professor

Center on Drug and Public Policy

Department of Pharmaceutical Health Services Research

University of Maryland School of Pharmacy

Baltimore, Maryland

Albert L. Tzeel, MD, MHSA, FACPE

National Medical Director

HumanaOne

Humana Inc

Milwaukee, Wisconsin

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in the activity,

and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty Disclosures

Within the past 12 months, the faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lawrence Blonde, MD, FACP, FACE

Consultant/advisory board member: Amylin, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Halozyme Therapeutics, Johnson & Johnson, MannKind Corporation, Merck & Co, Inc, Novo Nordisk, Orexigen, Roche, sanofi-aventis, Santarus, Inc, VeroScience

Grants/research support: Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche, sanofi-aventis

Lecturer: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb,

Daiichi Sankyo, Merck & Co, Inc, Novo Nordisk, Santarus, Inc, VeroScience

Receipt of payment for involvement in the preparation of this manuscript: Novo Nordisk

Stock ownership (spouse): Amylin, Pfizer

Viktor V. Chirikov, MS, has no relevant financial relationships to disclose.

Fadia T. Shaya, PhD, MPH, has no relevant financial relationships to disclose.

Albert L. Tzeel, MD, MHSA, FACPE

Consultant: Genentech, Inc

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have had with commercial interests related to the content of this CME activity:

Steve Casebeer, MBA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner have not had any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The publishing staff at The American Journal of Managed Care has no relevant financial relationships to disclose.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Download PDF: Participating Faculty: Improving Treatment Success Rates for Type 2 Diabetes: Balancing Safety, Cost, and Outcome